PERSANTINE TAB 50MG TABLET

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

DIPYRIDAMOLE

Доступна з:

BOEHRINGER INGELHEIM (CANADA) LTD LTEE

Код атс:

B01AC07

ІПН (Міжнародна Ім'я):

DIPYRIDAMOLE

Дозування:

50MG

Фармацевтична форма:

TABLET

Склад:

DIPYRIDAMOLE 50MG

Адміністрація маршрут:

ORAL

Одиниць в упаковці:

100

Тип рецепту:

Prescription

Терапевтична области:

MISCELLANEOUS VASODILATATING AGENTS

Огляд продуктів:

Active ingredient group (AIG) number: 0106621002; AHFS:

Статус Авторизація:

CANCELLED POST MARKET

Дата Авторизація:

2011-03-03

Характеристики продукта

_ _
_Product Monograph _
_Page 1 of 22 _
PRODUCT MONOGRAPH
Pr
PERSANTINE
®
Dipyridamole Tablets
Dipyridamole for Injection
50 mg and 75 mg tablets
5 mg/mL injectable ampoules
Coronary Vasodilator
Inhibitor of Platelet Adhesion and Aggregation
Boehringer Ingelheim Canada Ltd.
5180 South Service Road
Burlington, ON L7L 5H4
Date of Preparation:
March 15, 1995
Date of Revision:
May 20, 2005
Submission Control No: 092334
BI BPI number: 0248-02 (tablets), 0150-04 (ampoules)
_ _
_Product Monograph _
_Page 2 of 22_
Table of Contents
[To update, right-click anywhere in the Table of Contents and select
“Update Field”, “Update
entire table”, click OK.]
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................5
DRUG INTERACTIONS
....................................................................................................8
DOSAGE AND
ADMINISTRATION................................................................................9
OVERDOSAGE
..................................................................................................................9
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND
STABILITY..........................................................................................11
SPECIAL HANDLING INSTRUCTIONS
.......................................................................11
DOSAGE FORMS, COMPOSITION AND PACKAGING
...........................